Two Or More Separate Aryl-o-groups Patents (Class 514/734)
-
Patent number: 6649193Abstract: The invention is directed to therapeutic antioxidant compositions which are enhanced by the stabilized atomic hydrogen; one of the most potent antioxidants. Such products can be used for prophylactic and therapeutic purposes in treatment of cancer, diabetes, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases, skin diseases etc. The products described can be used independently or in combination with other drugs and treatment modalities. The products can also be used as dietetic products to aid in desired weigh loss. The described products can also be used to prevent oxidative and free radical damage to food and oxidation-prone industrial products. The invention also describes the methods to produce and stabilize atomic hydrogen and prepare and use such stabilized/encaged atomic hydrogen enhanced antioxidant compositions.Type: GrantFiled: June 9, 2000Date of Patent: November 18, 2003Assignee: Henceforth Hibernia Inc.Inventor: Miroslav Colic
-
Patent number: 6641800Abstract: Pressurized aerosol composition for administration by inhalation comprising a liquefied hydrofluoroalkane, a powdered medicament dispersed therein, and a suspending agent comprising a polymer soluble in the liquefied hydrofluoroalkane which is selected from polymers including recurring amide containing structural units, copolymers of amide containing units and carboxylic acid ester units, polyvinylacetate and acrylic acid/methacrylic acid ester copolymers.Type: GrantFiled: July 13, 2000Date of Patent: November 4, 2003Assignee: Fisons Ltd.Inventors: Suresh N Mistry, Mark Gibson
-
Publication number: 20030176511Abstract: The present invention relates compositions and methods for the prophylactic or therapeutic treatment of cardiovascular diseases, particularly restenosis and atherosclerosis. These compositions comprise an effective promotor of re-endothelialization, preferably probucol or an analogue thereof, and an inhibitor of lipoprotein oxidation, preferably a probucol-derived bisphenol. Alternatively, the said compositions may comprise a compound that possesses both re-endothelialization-promoting and lipoprotein oxidation-inhibitory effects. This invention further relates to compositions and methods for promoting re-endothelialization.Type: ApplicationFiled: February 28, 2003Publication date: September 18, 2003Inventor: Roland Stocker
-
Publication number: 20030166727Abstract: The present invention relates to cannabidiol derivatives and to pharmaceutical compositions comprising cannabidiol derivatives being antiinflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity.Type: ApplicationFiled: January 30, 2003Publication date: September 4, 2003Inventors: Raphael Mechoulam, Susana Tchilibon, Ester Fride, Lumir Hanus, Aviva Breuer, Ruth Gallily
-
Patent number: 6610750Abstract: A method of treating osteoarthritis, which is effective not only at targeting the symptoms of the disease, but also in interrupting, preventing, and controlling cartilage destruction, to thereby favorably alter the course of the disease, comprising the administration of an effective amount of rhein or a rhein derivative, preferably diacerein, either alone or in combination with at least one member selected from the group consisting of analgesics, antipyretics, cortico-steroids, anti-inflammatory agents, cyclooxygenase-2 inhibitors, and inflammatory cytokine inhibitors, to a subject in need of such treatment.Type: GrantFiled: September 15, 2000Date of Patent: August 26, 2003Assignee: Laboratoires NegmaInventors: Suzy Charbit, Francois Schutze, Alain Taccoen, Jean-Pierre Pelletier, Diego Provvedini
-
Patent number: 6610749Abstract: A method for reducing food intake in a subject and a method for reducing the levels of an endocrine in a subject comprising administering to the subject in need thereof an effective amount of a compound of the formula: wherein A is alkenyl, and each of Ra, Rb, Rc and Rd is herein defined.Type: GrantFiled: February 15, 2001Date of Patent: August 26, 2003Assignee: ARCH Development CorporationInventors: Shutsung Liao, Richard A. Hiipakka, Yung-Hsi Kao
-
Patent number: 6585989Abstract: Plastic films, fibers and articles are provided long-term antimicrobial activity with a combination of certain phenolic and inorganic antimicrobial agents. The plastic films, fibers and articles with antimicrobial activity exhibit superior resistance to discoloration, may be processed at high temperature, and maintain physical properties upon weathering, especially upon exposure to ultraviolet radiation.Type: GrantFiled: September 21, 2001Date of Patent: July 1, 2003Assignee: Ciba Specialty Chemicals CorporationInventors: Heinz Herbst, Urs Stadler
-
Patent number: 6572882Abstract: The invention relates to compositions based on derivatives of resveratrol having in particular a high stability as regards air and light.Type: GrantFiled: January 19, 2000Date of Patent: June 3, 2003Assignee: CaudalieInventors: Joseph Vercauteren, Chantal Castagnino, Jean-Claude Delaunay
-
Patent number: 6562834Abstract: A pharmaceutical combination for the treatment of cancers containing a stilbene derivative and a camptothecin is described.Type: GrantFiled: October 26, 2001Date of Patent: May 13, 2003Assignee: Aventis Pharma S. A.Inventor: Marie-Christine Bissery
-
Patent number: 6541038Abstract: A method for treating wood, characterized by impregnating wood with a metal-containing treating agent containing lignin and/or lignin derivatives and a metal, a metal compound, and/or a metal ion and oxidizing and/or macromolecularizing of the lignin and/or lignin derivatives in the wood to fix the metal component in the wood, and wood and woody materials obtained by the treating method. According to the method of the present invention, while effectively utilizing lignins, lignosulfonic acids, or lignosulfonic acid salts, leaching of the metal component can be suppressed to a low level to thereby retain the effects due to the incorporation of the metal components for a prolonged period.Type: GrantFiled: May 25, 2000Date of Patent: April 1, 2003Assignee: SDS Biotech K.K.Inventors: Keijitsu Tanaka, Hirobumi Aoki, Takashi Echigo
-
Patent number: 6540991Abstract: A stabilized insect mating disruption pheromone compositions comprising an insect pheromone and 2,2′-Methylenebis(6-t-butyl-p-cresol). Methods of use and microcapsules containing these compositions are also provided.Type: GrantFiled: April 6, 2001Date of Patent: April 1, 2003Assignee: 3M Innovative Properties CompanyInventors: Darryl F. Klassen, David J. Muir
-
Publication number: 20030059479Abstract: The object of the present invention is to provide a daily usable manes for exerting the tonic action inherent to royal jellies, and is solved by providing a cell activating agent comprising a royal jelly and trehalose.Type: ApplicationFiled: August 15, 2002Publication date: March 27, 2003Inventor: Toshio Miyake
-
Publication number: 20030053968Abstract: The present invention addresses the problem of excessive discoloration in hydroquinone compositions of a neutral pH. Antioxidants in the hydroquinone phase and inorganic or amino acyl cationic salts of acidic ascorbyl esters, preferably sodium metabisulfite and magnesium ascorbyl phosphate respectively, are effective in stabilizing such hydroquinone compositions, which are used in treatment of pigmentation disorders. Protected retinoid may be added to these compositions for additional skin benefit effects.Type: ApplicationFiled: May 23, 2001Publication date: March 20, 2003Inventors: Mitchell S. Wortzman, Philip J. Gordon, Eugene H. Gans, Bhiku G. Patel
-
Publication number: 20030046718Abstract: Transgenic animals that do not express functional SR-BI and ApoE develop severe atherosclerosis, by age four weeks in transgenic mice. Moreover, these animals exhibit progressive heart dysfunction by as early as age four weeks, and die by age nine weeks. This animal model has now been demonstrated to be useful as a screen for compounds which alleviate the symptoms of atherosclerosis and heart disease. Animals (Apo E−/− SR-BI +/−) were fed PROBUCOL beginning at the time of mating. Offspring are weaned at three weeks and fed PROBUCOL. In contrast to animals (Apo E−/− SR-BI −/−) not fed PROBUCOL, 50% of whom are dead at six weeks, all animals (Apo E−/− SR-BI −/−) on PROBUCOL have a normal phenotype (MRI of heart function, ECG, echocardiogram, histology) at six weeks. At seven to eight months, there is evidence of atherosclerosis and some myocardial infarction. This demonstrates that the compound has a preventative action.Type: ApplicationFiled: May 16, 2002Publication date: March 6, 2003Applicant: Massachusetts Institute of TechnologyInventors: Monty Krieger, Anne Braun, Helena E. Miettinen
-
Patent number: 6521669Abstract: The hydroxystilbenes are well suited for reducing or inhibiting the glycation of certain substrates, for example the proteins of nails and/or hair, advantageously to preventatively and/or curatively combat glycation-related aging of the nails/hair.Type: GrantFiled: July 14, 2000Date of Patent: February 18, 2003Assignee: Societe L'Oreal S.A.Inventors: Christel Liviero, Lionel Breton, Hervé Pageon
-
Publication number: 20030018060Abstract: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CO2RC wherType: ApplicationFiled: June 21, 2002Publication date: January 23, 2003Applicant: Novogen Research PTY LimitedInventors: Graham Edmund Kelly, George Eustace Joannou
-
Publication number: 20030003142Abstract: A superior skin depigmentation composition and a method for the depigmentation of skin is provided. The depigmenting composition contains effective amounts of hydroquinone and a retinoid.Type: ApplicationFiled: May 23, 2001Publication date: January 2, 2003Inventors: Mitchell S. Wortzman, Eugene H. Gans
-
Publication number: 20030004211Abstract: The present invention provides a composition that modulates the rate of sugar absorption and/or metabolism in a subject to whom the composition is administered. The composition includes active soluble fiber, one or more polyphenolic compounds, and a source of amino acids. The composition may be used dry in formulating foodstuffs and beverages. In a preferred embodiment, the composition is a component of a finished beverage, such as a carbonated soft drink.Type: ApplicationFiled: May 22, 2002Publication date: January 2, 2003Inventors: Frank Corsini, Richard L. Kozlenko, Joe A. Vinson
-
Publication number: 20030003121Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.Type: ApplicationFiled: April 25, 2002Publication date: January 2, 2003Applicant: National Agricultural Research Org.Inventors: Kenkou Tsuji, Mari Yamamoto, Keiko Kawamoto, Hirofumi Tachibana
-
Patent number: 6486203Abstract: A patient with an inflammatory disease of the head and neck is treated with a therapeutic amount of a selective inhibitor of cyclooxygenase-2 or a cyclooxygenase-2 inhibitor from a natural source. In one embodiment, a patient with a sore throat caused by tonsillitis or pharyngitis is treated with the topical application of a cyclooxygenase-2 inhibitor from a natural source. In other embodiments, patients with sore throat caused by tonsillitis or pharyngitis or a patient with sinusitis are treated by systemic administration of a selective inhibitor of cyclooxygenase-2. In another embodiment, a patient with periodontitis is treated by administration of a cyclooxygenase-2 inhibitor from a natural source.Type: GrantFiled: February 7, 2001Date of Patent: November 26, 2002Assignee: Cornell Research Foundation, Inc.Inventor: Andrew J. Dannenberg
-
Patent number: 6475526Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.Type: GrantFiled: June 5, 2001Date of Patent: November 5, 2002Inventor: Jeffrey B. Smith
-
Patent number: 6469055Abstract: It has been discovered that the stimulation of &bgr;-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising &bgr;-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by &bgr;-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of &bgr;-adrenergic receptors.Type: GrantFiled: February 5, 2001Date of Patent: October 22, 2002Assignee: Massachusetts Institute of TechnologyInventors: Robert K.K. Lee, Richard J. Wurtman
-
Patent number: 6455541Abstract: The present invention focuses upon a method for inhibiting bone resorption. This method involves administering a 5-lipoxygenase inhibitor to a subject in an amount inhibiting the effects of an osteoclast-stimulating factor. When the production of the osteoclast-stimulating factors such as PTH, PTHrp, IL-1, TNF, LT, 1,25(OH)2D3 or other factors which may stimulate the production of 5-LO metabolites via the 5-lipoxygenase pathway is inhibited, bone resorption markedly declines. The direct osteoclast-stimulating factors include leukotriene, peptidoleukotriene and 5-hydroxyeicosatetraenoic acid. Other factors yet to be identified or previously known may also be 5-lipoxygenase metabolites that stimulate bone resorption. While 5-lipoxygenase inhibitors may be substrate analogs or allosteric inhibitors, a substance which inhibits the activity of this enzyme may utilize other mechanisms (e.g., inhibition of 5-LO biosynthesis) and nevertheless function to inhibit bone resorption.Type: GrantFiled: May 8, 2000Date of Patent: September 24, 2002Assignee: Board of Regents, The University of Texas SystemInventors: Lynda F. Bonewald, G. R. Mundy, Wolf E. Gallwitz
-
Patent number: 6448294Abstract: A method of treating symptoms linked to menopause in warm-blooded animals by administering to warm-blooded animals in need thereof an amount of a compound of the formula wherein the substituents are defined as in the application sufficient to treat said symptoms.Type: GrantFiled: February 13, 2002Date of Patent: September 10, 2002Assignee: Aventis Pharma S.A.Inventor: Dominique Lesuisse
-
Patent number: 6414037Abstract: A method is provided for preventing or treating skin conditions, disorders or diseases, such as may be associated with or caused by inflammation, sun damage or natural aging. The method involves administration, preferably topical administration, of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing. Pharmaceutical formulations for use in conjunction with the aforementioned method are provided as well.Type: GrantFiled: October 29, 1999Date of Patent: July 2, 2002Assignee: PharmascienceInventors: John M. Pezzuto, Richard C. Moon, Mei-Shiang Jang, Aomar Ouali, Shengzhao Lin, Karla Slowing Barillas
-
Patent number: 6414017Abstract: Mammalian hair growth is reduced by applying to the skin a composition including an inhibitor of an enzyme involved in arachidonic acid metabolism.Type: GrantFiled: January 18, 2001Date of Patent: July 2, 2002Assignee: The Gillette CompanyInventors: Gurpreet S. Ahluwalia, Douglas Shander
-
Patent number: 6403652Abstract: A method for inhibiting methicillin drug resistant bacteria using a phenolic compound.Type: GrantFiled: June 30, 2000Date of Patent: June 11, 2002Assignee: Colgate-Palmolive CompanyInventors: John Brahms, Bruce Nascimbeni, Sukhvinder Sandhu
-
Publication number: 20020049244Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z), 8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.Type: ApplicationFiled: December 14, 2001Publication date: April 25, 2002Inventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
-
Patent number: 6369115Abstract: A dry powder formulation for treatment of pulmonary conditions, via inhalation, includes an effective amount of formoterol or a salt or solvate thereof, in a dry powder form, an effective amount of fluticasone, in a dry powder form, and an excipient. A method for preparing a physically stable dry powder formulation for inhalation includes the steps of micronizing a first active polar drug, a second active non-polar drug, and a polar excipient. The second non-polar active drug is first blended with the excipient to form an intermediate mixture. The intermediate mixture is then blended with the first active polar drug. The increased separation of the polar drug and polar excipient stabilizes the formulation.Type: GrantFiled: March 20, 2000Date of Patent: April 9, 2002Assignee: Dura Pharmaceuticals, Inc.Inventor: Gary Ward
-
Publication number: 20020037305Abstract: A method for destructive treatment of tumorous cells including the use of glycopropylene of retinoic acid in a pharmaceutical composition, a method for bladder irrigation having antitumoral properties including the use of a glycopropylene ester of retinoic acid together with a pharmaceutically compatible liquid vector, a method for treatment of nerve disorders including the use of a glycopropylene ester of retinoic acid for preparation of a pharmaceutical composition and a pharmaceutical composition for the same.Type: ApplicationFiled: October 1, 2001Publication date: March 28, 2002Inventor: Ammar Khodor
-
Patent number: 6328998Abstract: The use of L-carnitine, some alkanoyl L-carnitines and the pharmacologically acceptable salts thereof in combination with long-chain alkanols such as polycosanols, or polycosanol-bearing natural products or extracts thereof for the prevention and treatment of diseases caused by abnormal lipid metabolism, such as atherosclerosis, hypercholesterolemia, cardiovascular disorders and peripheral diabetic neuropathy.Type: GrantFiled: January 3, 2000Date of Patent: December 11, 2001Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Claudio Cavazza
-
Publication number: 20010047032Abstract: Polyhydroxylated aromatic compounds, and compositions containing them, are useful for the treatment of amyloidosis, especially Alzheimer's disease, and for the treatment of diseases characterized by &agr;-synuclein fibril formation, especially Lewy body disease and Parkinson's disease.Type: ApplicationFiled: December 26, 2000Publication date: November 29, 2001Inventors: Gerardo M. Castillo, Paula Y. Choi, Alan D. Snow
-
Patent number: 6322820Abstract: A composition of matter for treating hemorrhoids comprising a pharmaceutically acceptable carrier, between 1% and 10% by weight of zinc oxide, between 0.2% and 5% by weight of resorcinol and between 0.1% and 3% by weight of menthol. A preferred carrier is white petroleum jelly and the composition may further include hydrocortisone as an active ingredient.Type: GrantFiled: May 22, 2000Date of Patent: November 27, 2001Inventor: Sylvain Simoneau
-
Publication number: 20010039296Abstract: A method for preventing and or reducing the symptoms of menopause in women comprises identifying women having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising trans-resveratrol and other compounds that prevent or reduce the symptoms.Type: ApplicationFiled: March 23, 2001Publication date: November 8, 2001Inventors: Debasis Bagchi, Gary Troxel
-
Patent number: 6291524Abstract: A method for suppressing undesired viral growth in a host which comprises administering to the host an effective amount of a compound of the formula: wherein R1, R2, R3 and R4 are independently selected from the group consisting of HO—, CH3O— and CH3(C═O)O—. The method is exemplified by inhibiting Tat transactivation of a lentivirus and in suppressing Herpes simplex virus.Type: GrantFiled: June 25, 1997Date of Patent: September 18, 2001Assignee: Johns Hopkins UniversityInventors: Ru Chih C. Huang, John N. Gnabre
-
Publication number: 20010020043Abstract: The present invention provides a method of inhibiting the formation of pseudorabies particles in a host cell. The method involves administering an effective amount of a poly-hydroxylated stilbene, particularly resveratrol, to a herpes virus infected host cell. The present invention also provides a method of reducing or inhibiting the growth of Neisseria gonorrhea and Neisseria meningiditis in vitro and in vivo. The method comprises administering a composition comprising a therapeutically effective amount of a tri-hydroxylated stilbene to a growth surface which has come into contact or could come into contact with the bacterium.Type: ApplicationFiled: December 11, 2000Publication date: September 6, 2001Inventor: John Docherty
-
Patent number: 6280707Abstract: An oral prophalaxis paste includes a preselected grade and amount of abrasive material such as pumice clay or diatimoceous earth. The abrasive material is moistened with water and a moisture retention agent such as glycerin is included. A curing system is employed, such as using sodium silicate and methyl salicylate. The formulation provides antimicrobial properties by the inclusion of triclosan.Type: GrantFiled: December 15, 1998Date of Patent: August 28, 2001Assignee: Dentsply International Inc.Inventors: Kenneth S. Peterson, James M. Sherman, Connie Chilcott, Tse-Chong Wu
-
Patent number: 6221374Abstract: Disclosed are compositions containing biologically active compounds that slowly release the biologically active compound. These compositions may be directly incorporated into the locus to be protected or may be applied to a structure in a coating.Type: GrantFiled: May 6, 1998Date of Patent: April 24, 2001Assignee: Rohm and Haas CompanyInventors: Tirthankar Ghosh, Edwin H. Nungesser
-
Patent number: 6211247Abstract: A method for preventing or treating restenosis and for preventing the recurrence or progression of coronary heart disease is provided. The method involves administration of a selected active agent to a patient following coronary intervention, e.g., coronary artery bypass surgery, endarterectomy, heart transplantation, heart balloon angioplasty, atherectomy, laser ablation or endovascular stenting. The active agent comprises cis-resveratrol, trans-resveratrol, a mixture thereof, or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof. Administration may be oral, parenteral, or the like. Pharmaceutical compositions for use in conjunction with the therapeutic method are also provided.Type: GrantFiled: November 4, 1999Date of Patent: April 3, 2001Assignee: Pharmascience IncInventor: David William Goodman
-
Patent number: 6197832Abstract: A composition and method for reducing serum cholesterol in humans and animals is provided. The method comprises administering phytosterol and policosanol which together produce a synergistic effect in lowering serum cholesterol levels. Preferably the administered composition includes about 3.2:1 parts by weight of phytosterol and policosanol.Type: GrantFiled: September 14, 1999Date of Patent: March 6, 2001Inventor: Harlan Lee Sorkin, Jr.
-
Patent number: 6184248Abstract: It has been discovered that the stimulation of &bgr;adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising &bgr;-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by &bgr;-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of &bgr;-adrenergic receptors.Type: GrantFiled: November 8, 1999Date of Patent: February 6, 2001Inventors: Robert K. K. Lee, Richard J. Wurtman
-
Patent number: 6169110Abstract: Methods of accelerating skin rejuvenation and methods of skin care treatment are disclosed using a combination of vitamin A and alphahydroxy acids, such as the combination of vitamin A propionate and glycolic acid. The combination can be prepared in an alcohol-based carrier having concentrations ranging from approximately 0.01% to 10% vitamin A propionate, preferably 0.1% to 4%, and 0.1% to 30% glycolic acid, preferably 2% to 10% glycolic acid. In addition to alcohol, the carrier may also include propylene glycol, preservatives, thickeners and non-ionic surfactants or may be a cream or ointment-based formulation. The formulation is applied topically to the skin at a frequency which will produce a fine desquamation. The formulation may also be used to accelerate the penetration of other therapeutic agents into the skin.Type: GrantFiled: May 22, 1997Date of Patent: January 2, 2001Assignee: Vivant PharmaceuticalsInventor: James E. Fulton, Jr.
-
Patent number: 6149896Abstract: Cosmetic and cosmeceutical compositions which enhance repair of damage caused to human DNA caused by excessive exposure to sunlight or to other radiation causing such damage. The active ingredients are a synergistic combination of nor-dihydroguiaretic acid (NDGA) and niacinamide. Optional components are propyl gallate or other antioxidants. Composition may further contain sun-screen additives.Type: GrantFiled: February 5, 1999Date of Patent: November 21, 2000Inventors: Emanuel Riklis, deceased, by Ruth Riklis, legal representative, by Eran Riklis, legal representative, by Liatt Oren-Riklis, legal representative, by Eitan Riklis, legal representative
-
Patent number: 6147119Abstract: Compounds of formula (I), wherein [X] represents aromatic carbocyclic rings (A) and (B), where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are as defined in the description, salts thereof, a method and intermediates for preparing same, the use thereof as drugs, and pharmaceutical compositions containing same, are disclosed.Type: GrantFiled: September 28, 1998Date of Patent: November 14, 2000Assignee: Hoechst Marion RousselInventor: Dominique Lesuisse
-
Patent number: 6133279Abstract: Herein disclosed are therapeutic agents for renal diseases and organ preservatives containing a compound represented by the general formula (1): ##STR1## wherein X represents an oxygen atom or a group represented by the general formula (2): ##STR2## where n represents an integer from 0 to 2, R.sub.1 represents a hydrogen atom or an acyl group, R.sub.2 represents a hydrogen atom, a lower alkyl group or a lower alkenyl group, R.sub.3 represents a lower alkyl group, R.sub.4, R.sub.5 and R.sub.6, which may be the same or different, each represents a hydrogen atom or an optionally substituted alkyl group, and R.sub.6 further represents a formyl, carboxyl, lower alkoxycarbonyl or optionally substituted carbamoyl group, or R.sub.3 and R.sub.4 may be taken together to form a five-membered ring, or R.sub.5 and R.sub.6 may be taken together to form a cycloalkyl group, provided that when the five-membered ring formed by R.sub.3 and R.sub.4 and the benzene ring form benzofuran or benzo[b]thiophene, R.sub.6 is absent.Type: GrantFiled: December 17, 1998Date of Patent: October 17, 2000Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Osamu Cynshi, Yoshiaki Takashima, Kunio Tamura, Akira Ishikawa, Yoshiaki Kato
-
Patent number: 6124364Abstract: The hydroxystilbenes are well suited for promoting desquamation and/or stimulating epidermal renewal and/or combating intrinsic/extrinsic aging of the skin of a human subject in need of such treatment, by topically applying thereto, for such period of time as required to elicit the desired response, a therapeutically effective amount of at least one of said hydroxystilbenes.Type: GrantFiled: April 9, 1999Date of Patent: September 26, 2000Assignee: Societe L'Oreal S.A.Inventors: Lionel Breton, Nathalie Pineau
-
Patent number: 6103753Abstract: An intimal thickening inhibitory agent comprising, as an active ingredient, a compound represented by formula (1): ##STR1## wherein X represents an oxygen atom or a group of formula (2): ##STR2## wherein n represents an integer of from 0 to 2, R.sub.1 represents a hydrogen atom or an acyl group; R.sub.2 represents a hydrogen atom, a lower alkyl group or a lower alkenyl group; R.sub.3 represents a lower alkyl group; and R.sub.4, R.sub.5, and R.sub.6, which may be the same or different, each represent a hydrogen atom or a substituted or unsubstituted alkyl group; or R.sub.3 and R.sub.4 may be taken together to form a 5-membered ring; or R.sub.5 and R.sub.6 may be taken together to form a cycloalkyl group; provided that R.sub.6 is nil when R.sub.3 and R.sub.4 are taken together to form benzofuran or benzo[b]thiophene.Type: GrantFiled: May 6, 1998Date of Patent: August 15, 2000Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Osamu Cynshi, Reiko Sekimori, Yoshiaki Kato
-
Patent number: 6087391Abstract: Organic compounds containing at least one hydrophilic group are rendered soluble in fatty systems by the formation of a chemical complex with a carrier selected among fatty acid esters of polyhydric hydroxyalkanes having general formula (I) ##STR1## wherein R.sub.1 is H or --CH.sub.2 OR.sub.5, R.sub.2 is H or --CH.sub.2 OR.sub.6, and each of R.sub.3, R.sub.4, R.sub.5 and R.sub.6 is independently a saturated or unsaturated fatty acid moiety having 1-30 carbon atoms or a saturated fatty acid moiety having 1-3 carbon atoms, with the proviso that at least one of R.sub.3, R.sub.4, R.sub.5 and R.sub.6 is a saturated or unsaturated fatty acid moiety having 1-30 carbon atoms, R2 and at least one or, when any of R.sub.1 and R.sub.2 is not H, at least two of R.sub.3, R.sub.4, R.sub.5 and R.sub.6 is a saturated fatty acid moiety having 1-3 carbon atoms. Diacetates of common monoglycerides are especilally preferred as the carriers for forming such complexes.Type: GrantFiled: September 16, 1996Date of Patent: July 11, 2000Inventor: Morten Sloth Weidner
-
Patent number: 6080791Abstract: A method of preventing and treating a viral condition caused by an enveloped virus is described, comprising using a therapeutically effective amount of a compound selected from the group consisting of a substituted hydroquinone and the corresponding benzoquinone, wherein said hydroquinone comprises a 2-R.sup.1, 3-R.sup.2 -1,4-hydroquinone where at least one of R.sup.1 and R.sup.2 include a carbon linkage to the benzene ring of the hydroquinone. Particularly useful compounds include 5,8-dihydro-5,8-methano-1,4-naphthalenediol, 1,4-naphthoquinone, 3', 6'-dihydroxybenzo-norbornane, tert-butylhydroquinone, other diols, e.g. 1,5-naphthalenediol, and alkylated diols, e.g. 4-methoxy-1-naphthol.Type: GrantFiled: July 24, 1992Date of Patent: June 27, 2000Assignees: Seres Laboratories, Inc., University of CaliforniaInventors: Dale L. Bodian, Judith M. White, Irwin D. Kuntz, Jay F. Stearns, R. Bryan Yamasaki
-
Patent number: 6060500Abstract: This invention relates to a method for inhibiting bome resorption in a patient with periodotal disease by administering 3-[1-(4-chlorolbenzyl)-3-t-butyl-thio-t-isopropylindol-2-yl]-2,2dimethylpr opanoic acid.Type: GrantFiled: December 27, 1996Date of Patent: May 9, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Lynda F. Bonewald, G.R. Mundy, Wolf E. Gallwitz